Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

  • Jahan Ara
    Department of Pharmacology, Allegheny University, Philadelphia, PA 10912; Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032; Department of Neurology, Neuroscience and Pediatrics, Cornell University Medical College, New York, NY 10021; and Stokes Research Institute and Department of Biochemistry and Biophysics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104
  • Serge Przedborski
    Department of Pharmacology, Allegheny University, Philadelphia, PA 10912; Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032; Department of Neurology, Neuroscience and Pediatrics, Cornell University Medical College, New York, NY 10021; and Stokes Research Institute and Department of Biochemistry and Biophysics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104
  • Ali B. Naini
    Department of Pharmacology, Allegheny University, Philadelphia, PA 10912; Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032; Department of Neurology, Neuroscience and Pediatrics, Cornell University Medical College, New York, NY 10021; and Stokes Research Institute and Department of Biochemistry and Biophysics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104
  • Vernice Jackson-Lewis
    Department of Pharmacology, Allegheny University, Philadelphia, PA 10912; Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032; Department of Neurology, Neuroscience and Pediatrics, Cornell University Medical College, New York, NY 10021; and Stokes Research Institute and Department of Biochemistry and Biophysics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104
  • Rosario R. Trifiletti
    Department of Pharmacology, Allegheny University, Philadelphia, PA 10912; Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032; Department of Neurology, Neuroscience and Pediatrics, Cornell University Medical College, New York, NY 10021; and Stokes Research Institute and Department of Biochemistry and Biophysics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104
  • Joel Horwitz
    Department of Pharmacology, Allegheny University, Philadelphia, PA 10912; Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032; Department of Neurology, Neuroscience and Pediatrics, Cornell University Medical College, New York, NY 10021; and Stokes Research Institute and Department of Biochemistry and Biophysics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104
  • Harry Ischiropoulos
    Department of Pharmacology, Allegheny University, Philadelphia, PA 10912; Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, NY 10032; Department of Neurology, Neuroscience and Pediatrics, Cornell University Medical College, New York, NY 10021; and Stokes Research Institute and Department of Biochemistry and Biophysics, Children’s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, PA 19104

書誌事項

公開日
1998-06-23
DOI
  • 10.1073/pnas.95.13.7659
公開者
Proceedings of the National Academy of Sciences

この論文をさがす

説明

<jats:p> The decrement in dopamine levels exceeds the loss of dopaminergic neurons in Parkinson’s disease (PD) patients and experimental models of PD. This discrepancy is poorly understood and may represent an important event in the pathogenesis of PD. Herein, we report that the rate-limiting enzyme in dopamine synthesis, tyrosine hydroxylase (TH), is a selective target for nitration following exposure of PC12 cells to either peroxynitrite or 1-methyl-4-phenylpyridiniun ion (MPP <jats:sup>+</jats:sup> ). Nitration of TH also occurs in mouse striatum after MPTP administration. Nitration of tyrosine residues in TH results in loss of enzymatic activity. In the mouse striatum, tyrosine nitration-mediated loss in TH activity parallels the decline in dopamine levels whereas the levels of TH protein remain unchanged for the first 6 hr post MPTP injection. Striatal TH was not nitrated in mice overexpressing copper/zinc superoxide dismutase after MPTP administration, supporting a critical role for superoxide in TH tyrosine nitration. These results indicate that tyrosine nitration-induced TH inactivation and consequently dopamine synthesis failure, represents an early and thus far unidentified biochemical event in MPTP neurotoxic process. The resemblance of the MPTP model with PD suggests that a similar phenomenon may occur in PD, influencing the severity of parkisonian symptoms. </jats:p>

収録刊行物

被引用文献 (7)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ